Ozuriftamab vedotin (BA 3021) is an antibody-drug conjugate (ADC) composed of ozuriftamab, a conditionally active biologic (CAB) antibody against receptor tyrosine kinase-like orphan receptor 2 (ROR2) conjugated to monomethyl auristatin E, with potential antineoplastic activity.